IGF-1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Present on pituitary somatotroph cells |
| Signal pathway | Gs, cyclic AMP, protein kinase A | Sequence follows receptor activation |
| Main measured effect | Growth hormone release | Insulin-like growth factor 1 shifts indirectly |
| Half-life, binding form | Several days | Extended through serum albumin association |
| Half-life, unmodified form | About 30 minutes | Limited mainly by enzymatic cleavage |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
However, there are a few exceptions to this general rule, and enzymes such as aldose reductase, glucose-6-phosphate dehydrogenase, and methylenetetrahydrofolate reductase can use both coenzymes in some species.
Modafinil, sold under the brand name Provigil among others, is a central nervous system (CNS) stimulant medication used to treat narcolepsy, sleep apnea, and shift work sleep disorder. It is taken by mouth. Modafinil is a first-line treatment for narcolepsy in the United States and Europe. The mechanism of action is not fully understood, but modafinil acts mainly as an atypical dopamine reuptake inhibitor, increasing dopamine levels without the rapid or overt signaling seen with classical stimulants such as amphetamine or cocaine. Unlike these drugs, modafinil has low addiction and dependence potential and does not produce strong euphoria, which contributes to its classification as a Schedule IV controlled substance in the United States. It is a prescription medication in most countries. Modafinil is generally well-tolerated; common side effects include headache, nausea, anxiety, and insomnia. Rare but serious adverse effects include severe skin reactions such as Stevens-Johnson syndrome. Modafinil is contraindicated during pregnancy due to increased risk of birth defects. Modafinil is used off-label as a cognitive enhancer by students and professionals seeking improved focus. Research on cognitive effects in non-sleep-deprived individuals has yielded mixed results. Modafinil is banned in competitive sports by the World Anti-Doping Agency. Modafinil was developed in France in the 1970s by neurophysiologist Michel Jouvet. The drug was approved for medical use in France in 1994 and in the United States in 1998. Generic versions became available in the US in 2012.
=== 16 January === Senior US officials reported that the SAF had recently used chemical weapons against the RSF in rural areas at least twice. The US also sanctioned SAF chief General Abdel Fattah al-Burhan for the army's conduct in the war. The RSF said that it attacked fighters and vehicles in Kabkabiya belonging to the JDF between the SLM-Al Nur and the GSLF. The RSF called for a joint committee to investigate the incident.
Sources: en.wikipedia.org
=== Other research === As of July 2013, afamelanotide was in phase II and III clinical trials for vitiligo and other skin diseases. A medication for rheumatoid arthritis, tofacitinib, has been tested for the treatment of vitiligo. According to a 2021 review, JAK inhibitors like ruxolitinib show promise in targeting the IFN-γ-chemokine signaling axis implicated in vitiligo pathogenesis and improving NSV. In mid-2026, pharmaceutical corporation Pfizer announced positive phase III trial results of ritlecitinib, a kinas-inhibiting drug, to treat NSV. Additionally, a 2026 study published in The Lancet showed positive results with the JAK inhibitor upadacitinib. As of 2024, mitochondrial antioxidants, NRF2 inhibitors, and TBK1 inhibitors were emerging as potential therapeutic options to block the effects of melanocytic mtDNA release associated with vitiligo. The head of a 2025 Osaka Metropolitan University research team suggested that its discoveries, which included the presence of dormant pigment cells in vitiligo patches, could lead to new treatment approaches.
=== Dentition === Komodo dragons have ziphodont teeth, which are defined as teeth that are laterally flattened, recurved, and with serrated tooth crowns where the serrations have a dentine core and a very thin enamel outer layer. This is the same type of dentition observed in many extinct theropod dinosaurs. The teeth of the insectivorous juveniles in contrast are barely recurved, with fewer and less well-developed serrations that lack dentine cores.
=== RMI Staffing === Remote Medical International medical providers are available for onsite deployments operating in remote areas worldwide. Medical providers include experienced EMTs, paramedics, physician assistants, nurses, and doctors who respond to routine and emergent medical incidents. RMI medics are most commonly deployed on offshore seismic research vessels and land-based mineral exploration and production sites.
Sources: en.wikipedia.org
== Overview and history == The goal in rational protein design is to predict amino acid sequences that will fold to a specific protein structure. Although the number of possible protein sequences is vast, growing exponentially with the size of the protein chain, only a subset of them will fold reliably and quickly to one native state. Protein design involves identifying novel sequences within this subset. The native state of a protein is the conformational free energy minimum for the chain. Thus, protein design is the search for sequences that have the chosen structure as a free energy minimum. In a sense, it is the reverse of protein structure prediction. In design, a tertiary structure is specified, and a sequence that will fold to it is identified. Hence, it is also termed inverse folding. Protein design is then an optimization problem: using some scoring criteria, an optimized sequence that will fold to the desired structure is chosen. When the first proteins were rationally designed during the 1970s and 1980s, the sequence for these was optimized manually based on analyses of other known proteins, the sequence composition, amino acid charges, and the geometry of the desired structure. The first designed proteins are attributed to Bernd Gutte, who designed a reduced version of a known catalyst, bovine ribonuclease, and tertiary structures consisting of beta-sheets and alpha-helices, including a binder of DDT. Urry and colleagues later designed elastin-like fibrous peptides based on rules on sequence composition.
=== Role in cancer progression and therapy resistance === ITGA1 contributes to tumor progression by regulating survival, migration, invasion, and resistance to anticancer therapies. In Pancreatic Ductal Adenocarcinoma (PDAC), ITGA1-mediated collagen EMT signaling promotes the survival of mesenchymal tumor cell populations, metastatic dissemination, and resistance to gemcitabine treatment. Inhibition of ITGA1 increases sensitivity to chemotherapy, making treatment more effective and supporting its capacity as a potential therapeutic target. In glioma, ITGA1 contributes to temozolomide (TMZ) resistance by activating the PI3K/AKT/Bcl-2 signaling pathway. Increased ITGA1 activity promotes anti-apoptotic signaling which prevents tumor cells from apoptosizing therefore leading to survival of tumor cells. Suppressing ITGA1 increases apoptosis and improves TMZ sensitivity. ITGA1 expression in glioma is regulated by the hsa-miR01298-5p pathway, which directly binds the ITGA1 3' untranslated region to suppress ITGA1 expression. Increased ITGA1 reverses those effects, making resistance to chemotherapy more likely.
The vagina is the birth canal for the delivery of a baby. When labor nears, several signs may occur, including vaginal discharge and the rupture of membranes (water breaking). The latter results in a gush or small stream of amniotic fluid from the vagina. Water breaking most commonly happens at the beginning of labor. It happens before labor if there is a premature rupture of membranes, which occurs in 10% of cases. Among women giving birth for the first time, Braxton Hicks contractions are mistaken for actual contractions, but they are instead a way for the body to prepare for true labor. They do not signal the beginning of labor, but they are usually very strong in the days leading up to labor. As the body prepares for childbirth, the cervix softens, thins, moves forward to face the front, and begins to open. This allows the fetus to settle into the pelvis, a process known as lightening. As the fetus settles into the pelvis, pain from the sciatic nerves, increased vaginal discharge, and increased urinary frequency can occur. While lightening is likelier to happen after labor has begun for women who have given birth before, it may happen ten to fourteen days before labor in women experiencing labor for the first time. The fetus begins to lose the support of the cervix when contractions begin. With cervical dilation reaching 10 cm to accommodate the head of the fetus, the head moves from the uterus to the vagina. The elasticity of the vagina allows it to stretch to many times its normal diameter in order to deliver the child.
== History == Captopril, the first ACE inhibitor, is a functional and structural analog of a peptide derived from the venom of the jararaca, a Brazilian pit viper (Bothrops jararaca). Enalapril is a derivative, designed by scientists at Merck to overcome the rash and bad taste caused by captopril. Enalapril is actually a prodrug; the active metabolite is enalaprilat. The di-acid metabolite of enalapril, enalaprilat, and its lysine analogue lisinopril are potent inhibitors of angiotensin-converting enzyme (ACE); they do not contain sulphydryl groups. Both drugs can be assayed by high-pressure liquid chromatography and by radioimmunoassay and plasma ACE inhibition remains stable under normal storage conditions. It is therefore possible to study their pharmacokinetics as well as their pharmacodynamic effects in humans. Enalaprilat and lisinopril as well as ACE activity have been measured in blood taken during the course of two studies of the effects of these drugs on blood pressure and autonomic responsiveness. Lisinopril is a synthetic peptide derivative of captopril. Scientists at Merck created lisinopril by systematically altering each structural unit of enalaprilat, substituting various amino acids. Adding lysine at one end of the drug turned out to have strong activity and adequate bioavailability when given orally; analogs of that compound resulted in lisinopril, which takes its name from the discovery of lysine. Merck conducted clinical trials, and the drug was approved for hypertension in 1987 and congestive heart failure in 1993.
Sources: en.wikipedia.org
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.
It links the peptide to serum albumin after administration, which delays removal from circulation. Reported half-life shifts from roughly half an hour to several days as a result.
Most published work tracks serum growth hormone and insulin-like growth factor 1 over time. Sampling schedules and assay methods vary enough that figures are not directly comparable across reports.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.